All In Biotech

Drug Trial Radar · NCT05384626

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors (ALKOVE-1)

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

840

Planned (sponsor's estimate)

Start

Jun 9, 2022

Primary completion

Dec 2027

Study completion Jan 2028

Sponsor

Lead sponsor
Nuvalent Inc.Industry
Sponsor type
Industry
First posted
May 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors. Phase 1 will evaluate the overall safety and tolerability of neladalkib and will determine the RP2D and, if applicable, the maximum tolerated dose (MTD) of neladalkib in patients with advanced ALK+ solid tumors. Phase 2 will determine the objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR) of neladalkib at the RP2D. Secondary objectives will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS), and clinical benefit rate (CBR) of neladalkib in patients with advanced ALK-positive NSCLC and other solid tumors. A drug-drug interaction (DDI) sub-study will determine the effect of neladalkib on the pharmacokinetics of midazolam and repaglinide, as well as the effect of itraconazole on the pharmacokinetics of neladalkib, in patients with advanced ALK-positive NSCLC

Conditions

  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor

Interventions

  • Neladalkib (NVL-655)Drug

    Oral Tablet of Neladalkib (NVL-655)

  • MidazolamDrug

    Oral Solution of Midazolam

  • RepaglinideDrug

    Oral Tablet of Repaglinide

  • ItraconazoleDrug

    Oral Solution of Itraconazole

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicities (DLTs) (Phase 1)Time frame: Within the first 21 days of the first neladalkib (NVL-655) dose
  2. Recommended Phase 2 Dose (RP2D) (Phase 1)Time frame: Within 21 days of last patient dosed during escalation
  3. Objective Response Rate (ORR) (Phase 2)Time frame: 2-3 years after first patient dosed.
  4. Number of participants with treatment-emergent adverse events, as assessed by CTCAE, V5.0 (Phase 1)Time frame: Approximately 3 years
  5. Area under the curve of repaglinide (Phase 2 DDI sub-study)Time frame: Pre-dose and up to 24 hours post-dose
  6. Area under the curve of midazolam (Phase 2 DDI sub-study)Time frame: Pre-dose and up to 24 hours post-dose
  7. Area under the curve of neladalkib (NVL-655) (Phase 2 DDI sub-study)Time frame: Pre-dose and up to 24 hours post-dose

Locations

74 sites in 15 countries. Site status is shown where the registry gives one.

  • University of California Irvine Medical Center

    Orange, California · Recruiting

  • University of California, Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • Stanford Cancer Institute

    Stanford, California · Recruiting

  • University of Colorado Cancer Center

    Aurora, Colorado · Recruiting

  • Georgetown University Medical Center

    Washington D.C., District of Columbia · Recruiting

  • University of Miami; Sylvester Cancer Center

    Miami, Florida · Recruiting

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia · Recruiting

  • University of Chicago Medical Center

    Chicago, Illinois · Recruiting

  • John Hopkins University

    Baltimore, Maryland · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Henry Ford Cancer Institute

    Detroit, Michigan · Recruiting

  • Washington University School of Medicine Siteman Cancer Center

    St Louis, Missouri · Recruiting

  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • OSU Brain & Spine Hospital

    Columbus, Ohio · Recruiting

  • University of Pennsylvania, Abramson Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • Sarah Cannon

    Nashville, Tennessee · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Active not recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

  • Royal North Shore Hospital

    Sydney, New South Wales, Australia · Recruiting

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia · Recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia · Recruiting

  • Universitair Ziekenhuis Antwerpen (UZA)

    Antwerp, Belgium · Recruiting

  • Universitaire Ziekenhuizen Leuven Campus Gastthuisberg

    Leuven, Belgium · Recruiting

  • Cross Cancer Institute

    Edmonton, Alberta, Canada · Recruiting

  • BC Cancer Center

    Vancouver, British Columbia, Canada · Recruiting

  • The Ottawa Hospital Cancer Center

    Ottawa, Ontario, Canada · Recruiting

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

  • Centre Leon Berard

    Lyon, France · Recruiting

  • Chu De Nantes

    Nantes, France · Recruiting

  • Institut Claudius Regaud

    Toulouse, France · Recruiting

  • Institute Gustave Roussy

    Villejuif, France · Recruiting

  • Universitatsklinikum Koln - University Hospital Cologne

    Cologne, Germany · Recruiting

  • Universitätsklinikum Frankfurt

    Frankfurt, Germany · Recruiting

  • LungenClinic Grosshansdorf GmbH

    Großhansdorf, Germany · Recruiting

  • Universkitatsklinikum Heidelberg - University Hospital Heidelberg

    Heidelberg, Germany · Recruiting

  • Azienda Ospedaliera Universitaria Ospedali Riuniti Umberto

    Ancona, Italy · Recruiting

  • IRCCS Istituto Tumori "G. Paolo II"

    Bari, Italy · Recruiting

Showing 40 of 74 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.